Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Leukemia

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 119 articles:
HTML format
Text format



Single Articles


    April 2018
  1. ASSI R, Kantarjian HM, Kadia TM, Pemmaraju N, et al
    Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Cancer. 2018 Apr 16. doi: 10.1002/cncr.31398.
    PubMed     Text format     Abstract available


  2. KANTARJIAN HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, et al
    Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31370.
    PubMed     Text format     Abstract available


    March 2018
  3. CZERW T, Labopin M, Giebel S, Socie G, et al
    Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemi
    Cancer. 2018 Mar 30. doi: 10.1002/cncr.31354.
    PubMed     Text format     Abstract available


  4. GILL H, Yim R, Lee HKK, Mak V, et al
    Long-term outcome of relapsed acute promyelocytic leukemia treated with oral arsenic trioxide-based reinduction and maintenance regimens: A 15-year prospective study.
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31327.
    PubMed     Text format     Abstract available


  5. XUAN L, Wang Y, Huang F, Jiang E, et al
    Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31295.
    PubMed     Text format     Abstract available


  6. KANTARJIAN HM, Su Y, Jabbour EJ, Bhattacharyya H, et al
    Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
    Cancer. 2018 Mar 6. doi: 10.1002/cncr.31317.
    PubMed     Text format     Abstract available


  7. EFFICACE F, Castagnetti F, Martino B, Breccia M, et al
    Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31323.
    PubMed     Text format     Abstract available


    February 2018
  8. CIUREA SO, Labopin M, Socie G, Volin L, et al
    Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31311.
    PubMed     Text format     Abstract available


  9. SESTILI S, Labopin M, Ruggeri A, Velardi A, et al
    T-cell-depleted haploidentical stem cell transplantation results improve with time in adults with acute leukemia: A study from the Acute Leukemia Working Party of the European Society of Blood and Marrow Transplantation (EBMT).
    Cancer. 2018 Feb 22. doi: 10.1002/cncr.31310.
    PubMed     Text format     Abstract available


  10. HO G, Wun T, Muffly L, Li Q, et al
    Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.31296.
    PubMed     Text format     Abstract available


  11. PRINTZ C
    First person: Ali Bazarbachi, MD, PhD: The professor at the American University of Beirut has advanced the treatment of leukemia and cancer research in the Middle East and worldwide.
    Cancer. 2018;124:661-662.
    PubMed     Text format    


    January 2018
  12. JABBOUR EJ, DeAngelo DJ, Stelljes M, Stock W, et al
    Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
    Cancer. 2018 Jan 30. doi: 10.1002/cncr.31249.
    PubMed     Text format     Abstract available


  13. TALPAZ M, Saglio G, Atallah E, Rousselot P, et al
    Dasatinib dose management for the treatment of chronic myeloid leukemia.
    Cancer. 2018 Jan 25. doi: 10.1002/cncr.31232.
    PubMed     Text format     Abstract available


    December 2017
  14. BALTZELL KA, Shen HM, Krishnamurty S, Sison JD, et al
    Bovine leukemia virus linked to breast cancer but not coinfection with human papillomavirus: Case-control study of women in Texas.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31169.
    PubMed     Text format     Abstract available


  15. SASAKI K, Kantarjian H, O'Brien S, Ravandi F, et al
    Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2017 Dec 20. doi: 10.1002/cncr.31187.
    PubMed     Text format     Abstract available


  16. SALZER WL, Burke MJ, Devidas M, Chen S, et al
    Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31099.
    PubMed     Text format     Abstract available


  17. INABA H, Cao X, Han AQ, Panetta JC, et al
    Bone mineral density in children with acute lymphoblastic leukemia.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31184.
    PubMed     Text format     Abstract available


  18. TAI EW, Ward KC, Bonaventure A, Siegel DA, et al
    Survival among children diagnosed with acute lymphoblastic leukemia in the United States, by race and age, 2001 to 2009: Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5178-5189.
    PubMed     Text format     Abstract available


  19. ABAZA YM, Kadia TM, Jabbour EJ, Konopleva MY, et al
    Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
    Cancer. 2017;123:4851-4859.
    PubMed     Text format     Abstract available


  20. ROSENSTOCK AS, Niu J, Giordano SH, Zhao H, et al
    Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.
    Cancer. 2017 Dec 13. doi: 10.1002/cncr.31144.
    PubMed     Text format     Abstract available


  21. MARRIOTT CJC, Beaumont LF, Farncombe TH, Cranston AN, et al
    Body composition in long-term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.
    Cancer. 2017 Dec 12. doi: 10.1002/cncr.31191.
    PubMed     Text format     Abstract available


  22. ROBOZ GJ, Kantarjian HM, Yee KWL, Kropf PL, et al
    Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31138.
    PubMed     Text format     Abstract available


  23. SCHIFFER CA
    "Epigenetic" modification as therapy for acute myeloid leukemia.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31137.
    PubMed     Text format    


  24. HOWELL CR, Wilson CL, Ehrhardt MJ, Partin RE, et al
    Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study.
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31162.
    PubMed     Text format     Abstract available


  25. NEUKIRCHEN J, Lauseker M, Hildebrandt B, Nolting AC, et al
    Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis.
    Cancer. 2017;123:4608-4616.
    PubMed     Text format     Abstract available


    November 2017
  26. ZHENG DJ, Lu X, Schore RJ, Balsamo L, et al
    Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31085.
    PubMed     Text format     Abstract available


  27. GOLDSBY RE, Stratton KL, Raber S, Ablin A, et al
    Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report.
    Cancer. 2017 Nov 3. doi: 10.1002/cncr.31065.
    PubMed     Text format     Abstract available


  28. FRICK MA, Vachani CC, Bach C, Hampshire MK, et al
    Survivorship and the chronic cancer patient: Patterns in treatment-related effects, follow-up care, and use of survivorship care plans.
    Cancer. 2017;123:4268-4276.
    PubMed     Text format     Abstract available


    October 2017
  29. KANTARJIAN HM, Mamolo CM, Gambacorti-Passerini C, Cortes JE, et al
    Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy.
    Cancer. 2017 Oct 26. doi: 10.1002/cncr.31082.
    PubMed     Text format     Abstract available


  30. TIRIBELLI M, Michelutti A, Fanin R, Damiani D, et al
    ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31037.
    PubMed     Text format    


  31. SHORT NJ, Kantarjian H, Jabbour E
    Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.31036.
    PubMed     Text format    


  32. SHEN C, Zhao B, Liu L, Shih YT, et al
    Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
    Cancer. 2017 Oct 4. doi: 10.1002/cncr.31050.
    PubMed     Text format     Abstract available


    September 2017
  33. FATHI AT, Blonquist TM, Hernandez D, Amrein PC, et al
    Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31038.
    PubMed     Text format     Abstract available


  34. SCHEICH S, Lindner S, Koenig R, Reinheimer C, et al
    Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31045.
    PubMed     Text format     Abstract available


  35. BUCKLEY SA, Jimenez-Sahagun D, Othus M, Walter RB, et al
    Quality of life from the perspective of the patient with acute myeloid leukemia.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30982.
    PubMed     Text format     Abstract available


  36. PRINTZ C
    First person: Rudiger Hehlmann: The professor of medicine and founder of the European LeukemiaNet builds on his hard-won legacy of improving the survival rates of patients with leukemia.
    Cancer. 2017;123:3209-3210.
    PubMed     Text format    


    August 2017
  37. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


    July 2017
  38. LEGROS L, Nicolini FE, Etienne G, Rousselot P, et al
    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30885.
    PubMed     Text format     Abstract available


  39. JAIN P, Kantarjian HM, Ghorab A, Sasaki K, et al
    Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30864.
    PubMed     Text format     Abstract available


  40. JABBOUR E, Short NJ, Ravandi F, Huang X, et al
    A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Cancer. 2017 Jul 14. doi: 10.1002/cncr.30883.
    PubMed     Text format     Abstract available


  41. ALVAREZ E, Keegan T, Johnston EE, Haile R, et al
    Adolescent and young adult oncology patients: Disparities in access to specialized cancer centers.
    Cancer. 2017;123:2516-2523.
    PubMed     Text format     Abstract available


  42. MARINA NM, Liu Q, Donaldson SS, Sklar CA, et al
    Longitudinal follow-up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study.
    Cancer. 2017;123:2551-2560.
    PubMed     Text format     Abstract available


    June 2017
  43. ARIFFIN H, Azanan MS, Abd Ghafar SS, Oh L, et al
    Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging.
    Cancer. 2017 Jun 27. doi: 10.1002/cncr.30857.
    PubMed     Text format     Abstract available


  44. ZEIDAN AM, Hu X, Long JB, Wang R, et al
    Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30814.
    PubMed     Text format     Abstract available


  45. KANAGAL-SHAMANNA R, Jain P, Takahashi K, Short NJ, et al
    TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30810.
    PubMed     Text format     Abstract available


  46. RADICH JP
    Chronic myeloid leukemia: Global impact from a local laboratory.
    Cancer. 2017 Jun 6. doi: 10.1002/cncr.30776.
    PubMed     Text format    


    May 2017
  47. ALEXANDER TB, Wang L, Inaba H, Triplett BM, et al
    Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
    Cancer. 2017 May 30. doi: 10.1002/cncr.30791.
    PubMed     Text format     Abstract available


  48. LIN CJ, Vader JM, Slade M, DiPersio JF, et al
    Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.
    Cancer. 2017;123:1800-1809.
    PubMed     Text format     Abstract available


  49. STAHL M, Zeidan AM
    Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Cancer. 2017;123:1703-1713.
    PubMed     Text format     Abstract available


  50. LEHMANN V, Tuinman MA, Keim MC, Winning AM, et al
    Psychosexual development and satisfaction in long-term survivors of childhood cancer: Neurotoxic treatment intensity as a risk indicator.
    Cancer. 2017;123:1869-1876.
    PubMed     Text format     Abstract available


  51. MILLOT F, Dupraz C, Guilhot J, Suttorp M, et al
    Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents.
    Cancer. 2017 May 12. doi: 10.1002/cncr.30767.
    PubMed     Text format     Abstract available


  52. PERRY AM, Brunner AM, Zou T, McGregor KL, et al
    Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30639.
    PubMed     Text format     Abstract available


  53. MAURO MJ
    Running the marathon of chronic myeloid leukemia with no shoes (or without the right shoes)!
    Cancer. 2017 May 2. doi: 10.1002/cncr.30638.
    PubMed     Text format    


  54. SHIELD PW, Frost F, Finnimore JL, Wright RG, et al
    External quality assurance in nongynecologic cytology: The Australasian experience.
    Cancer. 2017;125:349-361.
    PubMed     Text format     Abstract available


    April 2017
  55. CHEUNG YT, Brinkman TM, Mulrooney DA, Mzayek Y, et al
    Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30742.
    PubMed     Text format     Abstract available


  56. SEGAL E, Martens M, Wang HL, Brazauskas R, et al
    Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
    Cancer. 2017 Apr 27. doi: 10.1002/cncr.30737.
    PubMed     Text format     Abstract available


  57. KHOURY HJ, Collins RH Jr, Blum W, Stiff PS, et al
    Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
    Cancer. 2017 Apr 14. doi: 10.1002/cncr.30696.
    PubMed     Text format     Abstract available


  58. BATTIPAGLIA G, Ruggeri A, Massoud R, El Cheikh J, et al
    Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30680.
    PubMed     Text format     Abstract available


  59. BODDU PC, Kantarjian HM, Ravandi F, Garcia-Manero G, et al
    Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30704.
    PubMed     Text format     Abstract available


  60. NICOLINI FE, Basak GW, Kim DW, Olavarria E, et al
    Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30558.
    PubMed     Text format     Abstract available


    March 2017
  61. NAGLER A, Labopin M, Beelen D, Ciceri F, et al
    Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30646.
    PubMed     Text format     Abstract available


  62. RYTTING ME, Jabbour EJ, O'Brien SM, Kantarjian HM, et al
    Acute lymphoblastic leukemia in adolescents and young adults.
    Cancer. 2017 Mar 22. doi: 10.1002/cncr.30624.
    PubMed     Text format     Abstract available


  63. YUCEL OK, Saliba RM, Rondon G, Ahmed S, et al
    Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30632.
    PubMed     Text format     Abstract available


  64. CHANG YJ, Wang Y, Mo XD, Zhang XH, et al
    Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30540.
    PubMed     Text format     Abstract available


    February 2017
  65. KONG JH, Winton EF, Heffner LT, Chen Z, et al
    Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
    Cancer. 2017 Feb 27. doi: 10.1002/cncr.30608.
    PubMed     Text format     Abstract available


  66. QU X, Othus M, Davison J, Wu Y, et al
    Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30626.
    PubMed     Text format     Abstract available


  67. PAVLU J, Labopin M, Zoellner AK, Sakellari I, et al
    Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.
    Cancer. 2017 Feb 17. doi: 10.1002/cncr.30604.
    PubMed     Text format     Abstract available


  68. LAUSEKER M, Hasford J, Saussele S, Kremers S, et al
    Smokers with chronic myeloid leukemia are at a higher risk of disease progression and premature death.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30636.
    PubMed     Text format     Abstract available


  69. JAIN P, Thompson PA, Keating M, Estrov Z, et al
    Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30596.
    PubMed     Text format     Abstract available


  70. MANYAM BV, Garsa AA, Chin RI, Reddy CA, et al
    A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30601.
    PubMed     Text format     Abstract available



  71. First Person: Clara Bloomfield, MD.
    Cancer. 2017;123:369-370.
    PubMed     Text format    


    January 2017
  72. MICHELIS FV, Gupta V, Zhang MJ, Wang HL, et al
    Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30567.
    PubMed     Text format     Abstract available


  73. WEISDORF DJ, Millard HR, Horowitz MM, Hyare PS, et al
    Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30536.
    PubMed     Text format     Abstract available


  74. EL-JAWAHRI A, Chen YB, Brazauskas R, He N, et al
    Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
    Cancer. 2017 Jan 19. doi: 10.1002/cncr.30546.
    PubMed     Text format     Abstract available


  75. NABBOUH AI, Hleihel RS, Saliba JL, Karam MM, et al
    Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30515.
    PubMed     Text format     Abstract available


  76. PRINTZ C
    Device rapidly measures cell growth and can help determine drug resistance in cancer.
    Cancer. 2017;123:10-11.
    PubMed     Text format    


    December 2016
  77. ROUSSELOT P, Prost S, Guilhot J, Roy L, et al
    Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30490.
    PubMed     Text format     Abstract available


  78. GORIN NC, Labopin M, Czerw T, Pabst T, et al
    Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the Eu
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30400.
    PubMed     Text format     Abstract available


    November 2016
  79. WAGNER B, da Silva Nardi F, Schramm S, Kraemer T, et al
    HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.
    Cancer. 2016 Nov 2. doi: 10.1002/cncr.30427.
    PubMed     Text format     Abstract available


    October 2016
  80. KOLLER PB, Kantarjian HM, Nogueras-Gonzalez GM, Jabbour E, et al
    Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30362.
    PubMed     Text format     Abstract available


  81. ISSA GC, Kantarjian HM, Yin CC, Qiao W, et al
    Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.
    Cancer. 2016 Oct 3. doi: 10.1002/cncr.30376.
    PubMed     Text format     Abstract available


    September 2016
  82. ANTILLON FG, Blanco JG, Valverde PD, Castellanos M, et al
    The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results.
    Cancer. 2016 Sep 28. doi: 10.1002/cncr.30257.
    PubMed     Text format     Abstract available


  83. RAVANDI F, Jorgensen J, Borthakur G, Jabbour E, et al
    Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia.
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30361.
    PubMed     Text format     Abstract available


  84. MUFFLY L, Lichtensztajn D, Shiraz P, Abrahao R, et al
    Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30322.
    PubMed     Text format     Abstract available


  85. RAO P, Li Y, Getz KD, Miller TP, et al
    Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals.
    Cancer. 2016 Sep 12. doi: 10.1002/cncr.30225.
    PubMed     Text format     Abstract available


  86. JABBOUR E, Short NJ, Jorgensen JL, Yilmaz M, et al
    Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
    Cancer. 2016 Sep 7. doi: 10.1002/cncr.30264.
    PubMed     Text format     Abstract available


    August 2016
  87. ARCHER NP, Perez-Andreu V, Scheurer ME, Rabin KR, et al
    Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30241.
    PubMed     Text format     Abstract available


  88. CREUTZIG U, Zimmermann M, Reinhardt D, Rasche M, et al
    Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups.
    Cancer. 2016 Aug 16. doi: 10.1002/cncr.30220.
    PubMed     Text format     Abstract available


  89. TAKAHASHI K, Kantarjian HM, Yang Y, Sasaki K, et al
    A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30197.
    PubMed     Text format     Abstract available


  90. SHORT NJ, Kantarjian HM, Sasaki K, Cortes JE, et al
    Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Cancer. 2016 Aug 10. doi: 10.1002/cncr.30262.
    PubMed     Text format     Abstract available


  91. SASAKI K, Jabbour EJ, Ravandi F, Short NJ, et al
    Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.
    Cancer. 2016 Aug 1. doi: 10.1002/cncr.30231.
    PubMed     Text format     Abstract available


    July 2016
  92. KADIA TM, Jain P, Ravandi F, Garcia-Manero G, et al
    TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30203.
    PubMed     Text format     Abstract available


    June 2016
  93. FREEMAN AT, Meyer AM, Smitherman AB, Zhou L, et al
    Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30139.
    PubMed     Text format     Abstract available


  94. GIDDINGS BM, Whitehead TP, Metayer C, Miller MD, et al
    Childhood leukemia incidence in California: High and rising in the Hispanic population.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30129.
    PubMed     Text format     Abstract available


  95. DEOL A, Sengsayadeth S, Ahn KW, Wang HL, et al
    Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30140.
    PubMed     Text format     Abstract available


  96. GIEBEL S, Czyz A, Ottmann O, Baron F, et al
    Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the acute leukemia working party of
    Cancer. 2016 Jun 16. doi: 10.1002/cncr.30130.
    PubMed     Text format     Abstract available


  97. BORTHAKUR G, Popplewell L, Boyiadzis M, Foran J, et al
    Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Cancer. 2016;122:1871-9.
    PubMed     Text format     Abstract available


  98. KAHN JM, Keegan TH, Tao L, Abrahao R, et al
    Racial disparities in the survival of American children, adolescents, and young adults with acute lymphoblastic leukemia, acute myelogenous leukemia, and Hodgkin lymphoma.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30089.
    PubMed     Text format     Abstract available


    May 2016
  99. THOMPSON PA, Stingo F, Keating MJ, Ferrajoli A, et al
    Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity.
    Cancer. 2016 May 16. doi: 10.1002/cncr.30069.
    PubMed     Text format     Abstract available


  100. FATHI AT, DeAngelo DJ, Stevenson KE, Kolitz JE, et al
    Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30037.
    PubMed     Text format     Abstract available


  101. HAAVISTO A, Henriksson M, Heikkinen R, Puukko-Viertomies LR, et al
    Sexual function in male long-term survivors of childhood acute lymphoblastic leukemia.
    Cancer. 2016 May 12. doi: 10.1002/cncr.29989.
    PubMed     Text format     Abstract available


  102. KANTARJIAN HM, Stein AS, Bargou RC, Grande Garcia C, et al
    Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from two phase 2 studies.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30031.
    PubMed     Text format     Abstract available


  103. GALLOWAY-PENA JR, Smith DP, Sahasrabhojane P, Ajami NJ, et al
    The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30039.
    PubMed     Text format     Abstract available


    April 2016
  104. AZUERO A
    A note on the magnitude of hazard ratios.
    Cancer. 2016;122:1298-9.
    PubMed     Text format    


  105. BORATE UM, Mineishi S, Costa LJ
    Reply to a note on the magnitude of hazard ratios.
    Cancer. 2016;122:1299-300.
    PubMed     Text format    


    March 2016
  106. KUNIN-BATSON AS, Lu X, Balsamo L, Graber K, et al
    Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29946.
    PubMed     Text format     Abstract available


  107. CZERW T, Labopin M, Gorin NC, Giebel S, et al
    Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the acute leukemia working party of the European Society for Blood and
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29990.
    PubMed     Text format     Abstract available


  108. SCHIFFER CA, Cortes JE, Hochhaus A, Saglio G, et al
    Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Cancer. 2016 Mar 21. doi: 10.1002/cncr.29933.
    PubMed     Text format     Abstract available


  109. BOSE P, Verstovsek S
    The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
    Cancer. 2016;122:681-92.
    PubMed     Text format     Abstract available


    February 2016
  110. TRICOLI JV, Blair DG, Anders CK, Bleyer A, et al
    Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.
    Cancer. 2016 Feb 5. doi: 10.1002/cncr.29871.
    PubMed     Text format     Abstract available


    January 2016
  111. DUPUIS LL, Lu X, Mitchell HR, Sung L, et al
    Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group.
    Cancer. 2016 Jan 15. doi: 10.1002/cncr.29876.
    PubMed     Text format     Abstract available


  112. LIPSHULTZ SE, Anderson LM, Miller TL, Gerschenson M, et al
    Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.
    Cancer. 2016 Jan 13. doi: 10.1002/cncr.29872.
    PubMed     Text format     Abstract available


    December 2015
  113. FALCHI L, Verstovsek S, Ravandi-Kashani F, Kantarjian HM, et al
    The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy.
    Cancer. 2015 Dec 30. doi: 10.1002/cncr.29852.
    PubMed     Text format     Abstract available


  114. HAKIM H, Dallas R, Zhou Y, Pei D, et al
    Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.
    Cancer. 2015 Dec 23. doi: 10.1002/cncr.29833.
    PubMed     Text format     Abstract available



  115. Recurrence, poor survival more likely in patients with acute myeloid leukemia who have certain mutations.
    Cancer. 2015;121:4275.
    PubMed     Text format    


  116. EL-JAWAHRI AR, Vandusen HB, Traeger LN, Fishbein JN, et al
    Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation.
    Cancer. 2015 Dec 9. doi: 10.1002/cncr.29818.
    PubMed     Text format     Abstract available


  117. CHURPEK JE, Marquez R, Neistadt B, Claussen K, et al
    Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29615.
    PubMed     Text format     Abstract available


  118. KARP JE, Wolff AC
    Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer.
    Cancer. 2015 Dec 7. doi: 10.1002/cncr.29613.
    PubMed     Text format    


    November 2015
  119. THOMPSON PA, O'Brien SM, Xiao L, Wang X, et al
    beta -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
    Cancer. 2015 Nov 20. doi: 10.1002/cncr.29794.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: